📊 ABUS Key Takeaways
Is Arbutus Biopharma Corp (ABUS) a Good Investment?
Arbutus Biopharma is in severe financial distress with collapsing revenues (-66% YoY), massive operating losses (-$32.9M), and negative free cash flow of -$35M, indicating the company is burning cash at an unsustainable rate. While the company maintains adequate liquidity with $22.4M cash and zero debt, current burn rate suggests less than 8 months of runway without significant operational turnaround or financing. The business fundamentals show a company in crisis requiring urgent revenue recovery or strategic capital infusion.
Arbutus Biopharma's fundamentals are weak: revenue fell 66% year over year, operating and net margins are deeply negative, and operating cash flow remains meaningfully negative. The balance sheet is a mitigating factor, with high liquidity, no long-term debt, and positive equity, but the current financial profile still depends on preserving cash while improving pipeline-related monetization or partnership revenue.
Why Buy Arbutus Biopharma Corp Stock? ABUS Key Strengths
- Strong liquidity position with $22.4M cash and no debt
- Low financial leverage with zero long-term debt provides flexibility
- Current ratio of 18.80x demonstrates short-term solvency
- Very strong liquidity with 18.80x current and quick ratios
- Debt-free capital structure with no long-term debt
- Positive stockholders' equity of $77.40M provides balance sheet cushion
ABUS Stock Risks: Arbutus Biopharma Corp Investment Risks
- Revenue collapsed 66% YoY indicating severe operational challenges
- Negative free cash flow of -$35M at burn rate exceeding remaining cash runway
- Operating losses of -$252% margin with no path to profitability demonstrated
- Limited financial runway of approximately 6-8 months at current burn rate
- Pharmaceutical sector requires successful clinical development and regulatory approvals
- Revenue is highly unstable, with a 66.0% year-over-year decline
- Severe and persistent losses shown by -252.2% operating margin and -228.2% net margin
- Heavy cash burn with -$34.96M operating cash flow and free cash flow pressures financial runway
Key Metrics to Watch
- Quarterly revenue trend and stabilization signals
- Monthly cash burn rate and runway projections
- Operating expense reductions and cost control measures
- Progress on clinical pipeline and regulatory milestones
- Financing activities and capital infusion announcements
- Quarterly operating cash burn relative to cash and equivalents
- Revenue durability and any improvement in operating loss trend
Arbutus Biopharma Corp (ABUS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 18.80x current ratio provides a solid financial cushion.
ABUS Profit Margin, ROE & Profitability Analysis
ABUS vs Healthcare Sector: How Arbutus Biopharma Corp Compares
How Arbutus Biopharma Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arbutus Biopharma Corp Stock Overvalued? ABUS Valuation Analysis 2026
Based on fundamental analysis, Arbutus Biopharma Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arbutus Biopharma Corp Balance Sheet: ABUS Debt, Cash & Liquidity
ABUS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arbutus Biopharma Corp's revenue has grown significantly by 28% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.38 indicates the company is currently unprofitable.
ABUS Revenue Growth, EPS Growth & YoY Performance
ABUS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $529.0K | $2.5M | $-0.04 |
| Q2 2025 | $1.7M | $2.5M | $0.01 |
| Q1 2025 | $1.5M | -$17.9M | $-0.10 |
| Q3 2024 | $1.3M | -$16.3M | $-0.10 |
| Q2 2024 | $1.7M | -$16.3M | $-0.10 |
| Q1 2024 | $1.5M | -$16.3M | $-0.10 |
| Q3 2023 | $4.7M | -$14.2M | $-0.12 |
| Q2 2023 | $4.7M | -$14.2M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arbutus Biopharma Corp Dividends, Buybacks & Capital Allocation
ABUS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arbutus Biopharma Corp (CIK: 0001447028)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ABUS
What is the AI rating for ABUS?
Arbutus Biopharma Corp (ABUS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABUS's key strengths?
Claude: Strong liquidity position with $22.4M cash and no debt. Low financial leverage with zero long-term debt provides flexibility. ChatGPT: Very strong liquidity with 18.80x current and quick ratios. Debt-free capital structure with no long-term debt.
What are the risks of investing in ABUS?
Claude: Revenue collapsed 66% YoY indicating severe operational challenges. Negative free cash flow of -$35M at burn rate exceeding remaining cash runway. ChatGPT: Revenue is highly unstable, with a 66.0% year-over-year decline. Severe and persistent losses shown by -252.2% operating margin and -228.2% net margin.
What is ABUS's revenue and growth?
Arbutus Biopharma Corp reported revenue of $13.0M.
Does ABUS pay dividends?
Arbutus Biopharma Corp does not currently pay dividends.
Where can I find ABUS SEC filings?
Official SEC filings for Arbutus Biopharma Corp (CIK: 0001447028) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABUS's EPS?
Arbutus Biopharma Corp has a diluted EPS of $-0.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ABUS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Arbutus Biopharma Corp has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ABUS stock overvalued or undervalued?
Valuation metrics for ABUS: ROE of -38.4% (sector avg: 15%), net margin of -228.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ABUS stock in 2026?
Our dual AI analysis gives Arbutus Biopharma Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ABUS's free cash flow?
Arbutus Biopharma Corp's operating cash flow is $-35.0M, with capital expenditures of $0.0. FCF margin is -268.2%.
How does ABUS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -228.2% (avg: 12%), ROE -38.4% (avg: 15%), current ratio 18.80 (avg: 2).